AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2861920
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day propranolol
Trial: 2861920
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day metoprolol
Trial: 27893526
Drug: Supplemental O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental O2 (10 l/min)
Trial: 24532523
Drug: Corticosteroid periarticular
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid periarticular injection (40 mg triamcinolone acetonide)
Trial: 24532523
Drug: Non-steroid periarticular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid periarticular injection
Trial: 24532523
Drug: Corticosteroid periarticular
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid periarticular injection
Trial: 20876699
Drug: Sugammadex 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 0.5 mg kg⁻¹
Trial: 20876699
Drug: Sugammadex 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 1.0 mg kg⁻¹
Trial: 20876699
Drug: Sugammadex 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2.0 mg kg⁻¹
Trial: 20876699
Drug: Sugammadex 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4.0 mg kg⁻¹
Trial: 18728368
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of fluoride toothpaste (1,450 ppm F as NaF)
Trial: 9656912
Drug: Topical nonsteroidal
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nonsteroidal anti-inflammatory drug gel (2 g, 5% ibuprofen)
Trial: 9656912
Drug: Systemic nonsteroidal
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic nonsteroidal anti-inflammatory drug tablets (400 mg ibuprofen)
Trial: 9656912
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel and placebo tablets
Trial: 2871887
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatments (excluding penicillamine)
Trial: 11600576
Drug: Up-regulation of
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-regulation of beta3 integrin subunit by epidermal growth factor or heparin-binding epidermal growth factor.
Trial: 11600576
Drug: Adhesion assays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesion assays using Ishikawa cells; alphavbeta3 integrins as primary receptors for osteopontin.
Trial: 22592586
Drug: 4-week group
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week group (tenofovir/lamivudine/efavirenz initiated at 4 weeks of TB treatment)
Trial: 22592586
Drug: 12-week group
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week group (tenofovir/lamivudine/efavirenz initiated at 12 weeks of TB treatment)
Trial: 20569666
Drug: Audiological rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audiological rehabilitation program for SPs (treatment program designed for SPs of PHLs); 90 min sessions, once a week for four weeks.
Trial: 20569666
Drug: N/A (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N/A (control SPs received no treatment).
Trial: 20569666
Drug: N/A (experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N/A (experimental SPs participated in treatment program).
Trial: 8994314
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A and B vaccine
Trial: 21366801
Drug: Monovalent hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent hepatitis A and B vaccines
Trial: 10077020
Drug: OptiMARK (gadoversetamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OptiMARK (gadoversetamide injection)
Trial: 7551366
Drug: Formoterol (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (24 micrograms twice a day for 2 weeks)
Trial: 31088304
Drug: Oral exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral exercise in addition to standard general care and diet counseling
Trial: 21934634
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg S-equol/day (EQL10)
Trial: 21934634
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg S-equol/day (EQL30)
Trial: 17919544
Drug: Buprenorphine 0.002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.002 mg/kg IV
Trial: 16199794
Drug: Free fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free fruit and vegetables for 6 months with instruction in meal planning and food preparation
Trial: 14613984
Drug: Trastuzumab combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab combined with chemotherapy
Trial: 1456485
Drug: Siriraj Spacer
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Siriraj Spacer with 2 puffs of albuterol (100 micrograms/puff)
Trial: 1553052
Drug: Heparin calcium
RxNorm normalized name: HEPARIN CALCIUM
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin calcium
Trial: 28403576
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg on day 1, followed by prasugrel 10 mg once daily on days 2 to 7, then vorapaxar 40 mg and prasugrel 10 mg on day 8, followed by vorapaxar 2.5 mg and prasugrel 10 mg orally once daily on days 9 to 28
Trial: 28403576
Drug: Vorapaxar 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar 40 mg on day 1, followed by vorapaxar 2.5 mg once daily on days 2 to 21
Trial: 24668226
Drug: Prasugrel 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 100 mg loading dose
Trial: 17174640
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg loading dose
Trial: 9671874
Drug: Liarozole (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liarozole (300 mg two times daily)
Trial: 9671874
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA) (100 mg two times daily)
Trial: 2725926
Drug: Sulglicotide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulglicotide (200 mg t.i.d)
Trial: 4758573
Drug: Digoxin tablets
RxNorm normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin tablets (0.25 mg)
Trial: 4758573
Drug: Absorption sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorption sensitivity to dissolution rate
Trial: 27159955
Drug: Reamberin (1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reamberin (1.5% solution, 10 mL/kg body weight intravenously once a day for up to 3 days)
Trial: 27159955
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment regimen (control group)
Trial: 25326035
Drug: Blended cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended cognitive behavioural treatment (10 face-to-face and 9 online sessions)
Trial: 25326035
Drug: Traditional face-to-face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional face-to-face cognitive behavioural treatment (20 weekly sessions)
Trial: 25326035
Drug: Blended cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended cognitive behavioural treatment
Trial: 25326035
Drug: Traditional face-to-face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional face-to-face cognitive behavioural treatment
Trial: 23173252
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy applied to specific acupoints (Baihui, Shenmen, Shenting, Sanyinjiao, Sishencong) 5 times a week for 8 weeks.
Trial: 12402727
Drug: Intramuscular meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine (up to 300 mg)
Trial: 9706926
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil 40 microg after lidocaine with epinephrine test dose
Trial: 7631947
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg.kg‐1
Trial: 8922769
Drug: Midazolam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.15 mg.kg‐1
Trial: 8922769
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg.kg‐1
Trial: 7631947
Drug: Midazolam (0.1‐0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1‐0.15 mg.kg‐1)
Trial: 2516707
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (4 micrograms/kg per minute for 3 hours)
Trial: 2516707
Drug: Metoclopramide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide infusion (10 mg as a bolus)
Trial: 2516707
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg/day for 3 months)
Trial: 925382
Drug: live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: live attenuated A/Scotland/74 (H3N2) virus vaccine
Trial: 31182263
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) for 12 months.
Trial: 31182263
Drug: More potent
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More potent antiplatelet agents (prasugrel and ticagrelor) compared to clopidogrel.
Trial: 30885259
Drug: Lysulin™ supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysulin™ supplementation (two tablets three times a day)
Trial: 29059197
Drug: Monthly email
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly email reminder intervention for doctors containing a list of patients overdue for a letter.
Trial: 22027850
Drug: Daily stretching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily stretching (at least 6 times per week)
Trial: 19570628
Drug: Hydroxysafflor yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxysafflor yellow A (HSYA) 35 mg
Trial: 19570628
Drug: Hydroxysafflor yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxysafflor yellow A (HSYA) 70 mg
Trial: 19570628
Drug: Hydroxysafflor yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxysafflor yellow A (HSYA) 140 mg
Trial: 11181472
Drug: Tezosentan 20
RxNorm normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan 20 mg/h
Trial: 11181472
Drug: Tezosentan 50
RxNorm normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan 50 mg/h
Trial: 9886750
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with insulin or oral hypoglycaemic agents
Trial: 9886750
Drug: Lower 2-h
RxNorm normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower 2-h plasma insulin
Trial: 8299317
Drug: MK-0963 10
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0963 10 mg
Trial: 8299317
Drug: MK-0963 25
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0963 25 mg
Trial: 4923928
Drug: Amylobarbitone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amylobarbitone 150 mg/day
Trial: 19804626
Drug: Micafungin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for subjects ≤ 40 kg)
Trial: 19887460
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (3 mg/kg/day)
Trial: 25624327
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment success
Trial: 10096642
Drug: Elevated EPQ
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated EPQ score on the neuroticism subscale, short duration of treatment, slow onset of response to treatment
Trial: 8677916
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (arm IV: i.a. and i.v. MMC + p.o. 5‐FU; arm V: i.v. MMC + p.o. 5‐FU) for rectal cancer
Trial: 8677916
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (arm I: i.p. and i.v. MMC + p.o. 5‐FU; arm II: i.v. MMC + p.o. 5‐FU) for colonic cancer
Trial: 8677916
Drug: Surgery only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery only (arm III for colonic cancer; arm VI for rectal cancer)
Trial: 6433099
Drug: High urea
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High urea dialysance treatments
Trial: 30367258
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment before each training session
Trial: 28880050
Drug: Active patches
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active patches
Trial: 28880050
Drug: Sham patches
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham patches
Trial: 22455413
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ixekizumab
Trial: 22455413
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg ixekizumab
Trial: 22455413
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg ixekizumab
Trial: 18182600
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention plus metformin
Trial: 18182600
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (750 mg/d)
Trial: 15684150
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (17P) therapy
Trial: 8932976
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g supplemental calcium daily
Trial: 2053000
Drug: Epidural injections
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injections of 80 mg triamcinolone acetonide plus 0.5% procaine hydrochloride in saline
Trial: 6407500
Drug: Amitriptyline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50 mg and 75 mg)
Trial: 6407500
Drug: Doxepin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (50 mg and 75 mg)
Trial: 6407500
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg, 75 mg and 100 mg)
Trial: 6407500
Drug: Doxepin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (75 mg)
Trial: 31806432
Drug: fentanyl target‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl target‐controlled infusion (fTCI)
Trial: 25356046
Drug: pH capsule
RxNorm normalized name: Xymogen Panxyme PH Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH capsule
Trial: 25356046
Drug: Conventional catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional catheter and pH capsule
Trial: 20402816
Drug: 5-day amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-day amoxicillin (1 g BID) followed by tetracycline (500 mg QID) and metronidazole (500 mg TID) for 9 days
Trial: 20402816
Drug: 14-day amoxicillin
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 14-day amoxicillin (1 g BID) followed by tetracycline (500 mg QID), metronidazole (500 mg TID), and amoxicillin (1 g BID) for 9 days
Trial: 12433733
Drug: High pretreatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High pretreatment serum concentration of bFGF (S-bFGF >= 17 pg/ml)
Trial: 12433733
Drug: Low pretreatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pretreatment serum concentration of bFGF (S-bFGF < 17 pg/ml)
Trial: 12433733
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with extensive-stage disease and high S-bFGF (>= 17 pg/ml)
Trial: 10341329
Drug: Candidate standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate standard CC (liquid preparation)
Trial: 8444211
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K supplementation at birth (n = 22)
Trial: 8444211
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) vitamin K supplementation at birth (n = 18)
Trial: 3021487
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (Tilade 4 mg q.i.d.)
Trial: 27976591
Drug: Pulsed high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed high-intensity laser therapy (HILT) with total energy of 1500 J through three phases/3 sessions/week for three consecutive months
Trial: 27976591
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser therapy with the same physical therapy programme
Trial: 27179167
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of RF and ultrasound cavitation
Trial: 23265634
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT; Coping Cat)
Trial: 23265634
Drug: Medication (sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (sertraline [SRT])
Trial: 23265634
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and medication
Trial: 16534103
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose Coenzyme Q10 (CoQ10) at preferred dose (either 1800 mg or 2700 mg)
Trial: 10934787
Drug: Glipizyd tabl.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizyd tabl. 5 mg
Trial: 10934787
Drug: Glibenese tabl.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenese tabl. 5 mg
Trial: 9887853
Drug: Five-day standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day standardized family-oriented clinical asthma training program with monthly follow-up for six months (Group 1)
Trial: 9887853
Drug: Regular medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular medical treatment according to international guidelines without a training program (Control Group)
Trial: 3142349
Drug: Erythromycin estolate
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate (500 mg)
Trial: 26083537
Drug: Erythromycin lactobionate,
RxNorm normalized name: Erythromycin Lactobionate, lactobionate 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin lactobionate, 3 mg/kg, administered intravenously 15 minutes before tracheal intubation
Trial: 26083537
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 15 minutes before tracheal intubation
Trial: 16300126
Drug: Distal Active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal Active Concept therapy
Trial: 11196233
Drug: Edgewise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edgewise therapy (Control)
Trial: 8769679
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment (continuous 17‐beta‐estradiol 2 mg and norethisterone acetate 1 mg per day)
Trial: 8769679
Drug: Transdermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapy (patches delivering continuous 17‐beta‐estradiol 0.05 mg/day with sequential oral medroxyprogesterone acetate 10 mg/day for 12 days/cycle)